What is this study trying to find out about borrelia infections?

This study aims to describe the clinical, biological, and radiological features of disseminated borreliosis in patients treated with anti-CD20 antibodies. It focuses on understanding how the infection presents and progresses in this specific group. The research is sponsored by the University Hospital, Strasbourg, France.

Who may be eligible for this borrelia infections clinical trial?

Participants must be 1 year or older and have confirmed disseminated borreliosis diagnosed within 24 months after anti-CD20 antibody treatment. The trial is open to all genders. Participants must agree to take part in the study. Please review eligibility criteria for more details.

Is there any cost to participate in this borrelia infections clinical trial?

Study-related care, including all trial visits and data collection, is provided at no cost. Personal travel and related expenses may vary and are not guaranteed to be covered. Participants should plan accordingly.

Actively Recruiting

Age: 1Year +

All Genders

ID07343089

Study of Disseminated Borreliosis in Patients Treated with Anti-CD20 Antibodies in France

Led by University Hospital, Strasbourg, France · Updated on 2026-01-15

100

Participants Needed

Research Sites

4 weeks

Total Duration

AI-Summary

What this Trial Is About

This research investigates cases of disseminated borreliosis, an infection caused by Borrelia burgdorferi sl. and Borrelia miyamotoi, in patients who have received treatment with anti-CD20 monoclonal antibodies. The study aims to clinically, biologically, radiologically, and pharmacologically describe these cases to better understand the infection among this specific patient group in France. The study is observational and collects data from patients who developed disseminated borreliosis within 24 months after receiving anti-CD20 therapy between January 2010 and July 2025. It does not involve administering treatments but focuses on monitoring and describing the diseases presentation and course. Participants will be evaluated for up to 12 months, during which researchers will document the clinical presentation of borreliosis cases. The study involves collecting medical information and biological data to characterize the infection. There is no intervention, and participants usual medical care continues throughout the observation period.

CONDITIONS

Brief Title

A Multicenter Real-life Study of Disseminated Borreliosis Cases Occurring in Patients Receiving Anti-CD20 Treatment in France

Who Can Participate

Age: 1Year +

All Genders

Eligibility Criteria

You may qualify if you...

Minor or adult subject
Confirmed disseminated borreliosis by molecular biology (Borrelia burgdorferi sl. or Borrelia miyamotoi)
Diagnosis within 24 months of receiving anti-CD20 monoclonal antibody treatment between January 1, 2010, and July 30, 2025

You will not qualify if you...

Refusal to participate in the study

Research Team

Pierre BOYER, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here